Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$69.86
-2.9%
$27.70
$4.77
$75.51
$5.43B0.563.25 million shs1.42 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$109.39
+4.0%
$105.71
$75.56
$139.13
$5.25B0.51630,955 shs589,197 shs
89BIO stock logo
ETNB
89BIO
$9.14
+1.1%
$9.93
$4.16
$11.84
$1.34B1.281.46 million shs2.09 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$78.24
+2.1%
$78.94
$55.53
$113.51
$5.50B1.3517,548 shs284,968 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-2.86%+1.11%+691.12%+1,066.21%+537.37%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+3.95%+5.94%-2.62%+2.02%+28.92%
89BIO stock logo
ETNB
89BIO
+1.11%-3.59%-17.81%+19.63%+13.97%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
+2.13%+1.31%-7.51%+10.20%+9.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3.7504 of 5 stars
4.64.00.00.03.30.80.6
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.8221 of 5 stars
4.53.00.04.52.54.20.6
89BIO stock logo
ETNB
89BIO
1.9638 of 5 stars
3.52.00.00.01.80.80.6
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.1031 of 5 stars
4.51.00.00.02.33.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3.13
Buy$92.3332.18% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.07
Buy$178.0062.72% Upside
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.29187.59% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.09
Buy$119.6052.86% Upside

Current Analyst Ratings Breakdown

Latest ETNB, NUVL, ABVX, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
89BIO stock logo
ETNB
89BIO
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.00
8/5/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$173.00 ➝ $176.00
8/5/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.00
8/4/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$150.00
7/29/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.00
7/29/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$74.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$45.00 ➝ $101.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$42.00 ➝ $70.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $101.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$71.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$0.69 per shareN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M14.15N/AN/A$1.46 per share74.92
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.52 per shareN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$13.09 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$190.71MN/A0.00N/AN/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.07N/A38.79N/A-49.88%-283.22%-33.06%N/A
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%N/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%8/14/2025 (Estimated)

Latest ETNB, NUVL, ABVX, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
89BIO stock logo
ETNB
89BIO
-$0.49-$0.71-$0.22-$0.71N/AN/A
8/7/2025Q2 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.27-$1.31-$0.04-$1.39N/AN/A
8/4/2025Q2 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
1.29
1.25
1.25
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.66
1.57
1.51
89BIO stock logo
ETNB
89BIO
0.07
15.19
18.03
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
13.57
13.57

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
89BIO stock logo
ETNB
89BIO
N/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.30%
89BIO stock logo
ETNB
89BIO
2.60%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6175.55 millionN/ANot Optionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.90 million38.77 millionOptionable
89BIO stock logo
ETNB
89BIO
40148.31 million144.45 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4071.81 million64.48 millionOptionable

Recent News About These Companies

Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)
Nuvalent (NUVL) Projected to Post Quarterly Earnings on Thursday
Nuvalent (NUVL) Gets a Buy from Goldman Sachs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$69.86 -2.05 (-2.86%)
Closing price 08/13/2025 03:59 PM Eastern
Extended Trading
$69.81 -0.04 (-0.06%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$109.39 +4.16 (+3.95%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$107.47 -1.92 (-1.76%)
As of 08/13/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

89BIO stock logo

89BIO NASDAQ:ETNB

$9.14 +0.10 (+1.11%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$9.14 -0.01 (-0.05%)
As of 08/13/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$78.24 +1.63 (+2.13%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$78.28 +0.04 (+0.04%)
As of 08/13/2025 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.